BTdCPU is an activator of HRI (heme-regulated eIF2α kinase) with anticancer activity. It has the ability to induce apoptosis in resistant cells and promote phosphorylation of eIF2α. In multiple myeloma, the eIF2-alpha kinase HRI is a novel therapeutic target. In dex-resistant cells, combination therapy utilizing BTdCPU, an HRI activator, and rapamycin, an mTOR inhibitor, showed additive effects on apoptosis. Therefore, targeted activation of the eIF2α kinase HRI represents a new therapeutic target for MM that can complement existing therapeutic approaches.
Physicochemical Properties
Molecular Formula | C13H8CL2N4OS |
Molecular Weight | 339.199818611145 |
Exact Mass | 337.98 |
Elemental Analysis | C, 46.03; H, 2.38; Cl, 20.90; N, 16.52; O, 4.72; S, 9.45 |
CAS # | 1257423-87-2 |
Related CAS # | 1257423-87-2 |
PubChem CID | 49787174 |
Appearance | White to off-white solid powder |
Density | 1.664±0.06 g/cm3(Predicted) |
LogP | 3.7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 2 |
Heavy Atom Count | 21 |
Complexity | 389 |
Defined Atom Stereocenter Count | 0 |
SMILES | ClC1=C(C=CC(=C1)NC(NC1=CC=C2C(=C1)SN=N2)=O)Cl |
InChi Key | NUUSUAWULNXMGF-UHFFFAOYSA-N |
InChi Code | InChI=1S/C13H8Cl2N4OS/c14-9-3-1-7(5-10(9)15)16-13(20)17-8-2-4-11-12(6-8)21-19-18-11/h1-6H,(H2,16,17,20) |
Chemical Name | 1-(1,2,3-benzothiadiazol-6-yl)-3-(3,4-dichlorophenyl)urea |
Synonyms | BTdCPU |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | HRI |
ln Vitro | BTdCPU (10 μM; 4, 8 h) BTdCPU causes eIF2α phosphorylation and encourages MM cell death [1]. Dex-resistant primary MM cells are cytotoxic to BTdCPU (10 μM; 4, 8 h) [1]. |
ln Vivo | In a mouse xenograft mammary tumor model, BTdCPU (175 mg/kg; intraperitoneal injection; once daily for 21 days) suppresses tumor growth without causing toxicity [2]. |
Cell Assay |
Western Blot Analysis[1] Cell Types: Bone marrow mononuclear cells (MNC) from multiple myeloma (MM) patients or healthy donors Tested Concentrations: 10 μM Incubation Duration: 0, 4, 8 hrs (hours) Experimental Results: In MM patient cells Induces early expression of CHOP but not in healthy bone marrow mononuclear cells (MNC). |
Animal Protocol |
Animal/Disease Models: Female nude mouse (mouse xenograft mammary tumor model) [2]. Doses: 175 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day for 21 days Experimental Results: Experimental Results:Complete tumor stasis that persisted for the remainder of the 3-week study, showing good safety in mice. |
References |
[1]. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res. 2017 Apr;55:23-32. [2]. Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target. Nat Chem Biol. 2011 Jul 17;7(9):610-6. |
Solubility Data
Solubility (In Vitro) | DMSO: 68~125 mg/mL (200.4~368.5 mM) |
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.9481 mL | 14.7406 mL | 29.4811 mL | |
5 mM | 0.5896 mL | 2.9481 mL | 5.8962 mL | |
10 mM | 0.2948 mL | 1.4741 mL | 2.9481 mL |